Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study

Documenti analoghi

• Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
  di: Naganuma, Makoto, et al.
  Pubblicazione: (2017)
• Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
  di: Naganuma, Makoto, et al.
  Pubblicazione: (2016)
• Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
  di: Naganuma, Makoto, et al.
  Pubblicazione: (2019)
• Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
  di: Hibi, Toshifumi, et al.
  Pubblicazione: (2020)
• First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
  di: Kobayashi, Taku, et al.
  Pubblicazione: (2015)